美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Rapport Therapeutics, Inc.

24.99

+0.12000.48%

盤後：24.990.00000.00%16:31 EDT

成交量：32.62萬

成交額：807.35萬

市值：11.52億

市盈率：-9.97

高：25.31

開：24.52

低：24.25

收：24.87

52周最高：42.27

52周最低：6.43

股本：4,611.33萬

流通股本：1,496.00萬

量比：0.72

換手率：2.18%

股息：- -

股息率：- -

每股收益(TTM):-2.5062

每股收益(LYR):-3.7760

淨資產收益率：-29.42%

總資產收益率：-20.14%

市淨率：4.37

市盈率(LYR):-6.62

資料載入中...

總覽公司新聞公告

美國研究綜述-Chewy、Phillips 66、Vimeo

美國研究綜述-Chewy、Phillips 66、Vimeo

美股週三早盤專注於中樞神經系統（CNS）疾病創新療法研發的生物製藥公司Rapport Therapeutics股價重挫此

生物製藥公司Rapport重挫18.8%，此前完成2.5億美元的公開發行

环球市场播报

BUZZ-Rapport Therapeutics 募資 2.5 億美元后業績下滑

Rapport Therapeutics Inc.按每股26.00美元價格公開發行960萬股普通股

美國研究綜述-IQVIA Holdings、Reliance、United Therapeutics

Pmv Pharmaceuticals, Inc.盤中異動股價大跌5.14%報1.39美元

異動解讀 | 癲癇藥物臨牀試驗成功，Rapport Therapeutics盤前大漲171.59%

Rapport Therapeutics公佈局灶性癲癇發作試驗積極結果

BUZZ-癲癇藥物在中期試驗中達到主要目標，Rapport Therapeutics 公司業績大漲

Rapport Therapeutics股價盤前大漲75.5%，局灶性癲癇發作治療藥物中期試驗數據表現積極

Rapport Therapeutics, Inc.公佈Rap-219治療局灶性癲癇發作患者2a期臨牀試驗積極頂線結果

Rapport Therapeutics將於2025年9月8日週一公佈Rap-219治療局灶性癲癇發作2a期臨牀試驗的初步數據

預計 Rapport Therapeutics Inc 每股虧損 83 美分 - 財報前瞻

【納斯達克生物科技指數收漲超2%】成分股Oric Pharma收漲33.50%，Erasca漲32.73%，Tango Therapeutics漲20.10%表現第三。萊斯康製藥則收跌5.66%跌幅第三大，Rapport Therapeutics跌10.46%，Intellia Therapeutics也跌22.88%。

Rapport Therapeutics, Inc.盤中異動早盤股價大漲5.18%報10.56美元

Rapport Therapeutics, Inc.盤中異動快速拉昇9.59%報11.20美元

Rapport Therapeutics, Inc.2025財年第一財季實現淨利潤-24.06百萬美元，同比減少6.13%

Rapport Therapeutics, Inc.盤中異動下午盤急速拉昇5.48%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/RAPP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":24.99,"timestamp":1760731200000,"preClose":24.87,"halted":0,"volume":326152,"hourTrading":{"tag":"盘后","latestPrice":24.99,"preClose":24.99,"latestTime":"16:31 EDT","volume":4577,"amount":114379.23,"timestamp":1760733118536},"delay":0,"floatShares":14959986,"shares":46113305,"eps":-2.506155,"marketStatus":"休市中","change":0.12,"latestTime":"10-17 16:00:00 EDT","open":24.52,"high":25.31,"low":24.25,"amount":8073514.42368,"amplitude":0.042622,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.506155,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":7,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":24.87,"postHourTrading":{"tag":"盘后","latestPrice":24.99,"preClose":24.99,"latestTime":"16:31 EDT","volume":4577,"amount":114379.23,"timestamp":1760733118536},"volumeRatio":0.7203343975727433,"impliedVol":0.8226,"impliedVolPercentile":0.4469},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","floatShares":14959986,"roa":"-20.14%","roe":"-29.42%","lyrEps":-3.775953,"volumeRatio":0.7203343975727433,"shares":46113305,"dividePrice":0,"high":25.31,"amplitude":0.042622,"preClose":24.87,"low":24.25,"week52Low":6.43,"pbRate":"4.37","week52High":42.2685,"institutionHeld":0,"latestPrice":24.99,"eps":-2.506155,"divideRate":0,"volume":326152,"delay":0,"ttmEps":-2.506155,"open":24.52,"prevYearClose":17.74,"prevWeekClose":26.5,"prevMonthClose":29.7,"prevQuarterClose":29.7,"fiveDayClose":26.5,"twentyDayClose":26.36,"sixtyDayClose":16.62},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAPP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-07","symbol":"RAPP","fiscalQuarterEnding":"2025/06","expectedEps":-0.87,"name":null,"time":"盤前","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.75},{"market":"US","date":"2025-05-08","symbol":"RAPP","fiscalQuarterEnding":"2025/03","expectedEps":-0.77,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-11","symbol":"RAPP","fiscalQuarterEnding":"2024/12","expectedEps":-0.62,"name":null,"time":"盤前","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-0.57},{"market":"US","date":"2024-11-07","symbol":"RAPP","fiscalQuarterEnding":"2024/09","expectedEps":-0.57,"name":null,"time":"盤前","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAPP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAPP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1758168000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RAPP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RAPP","date":"2025-10-16","current":-9.97145,"percent":0.233918,"low":-19.654107,"twenty":-13.865457,"median":-9.199351,"eighty":-5.252778,"high":-3.640031,"avg":-9.609614,"sd":4.1794,"marketCap":1188794738},"quantilePoints":[{"date":"2024-06-07","current":-14.341434,"twenty":-13.293406,"median":-11.721364,"eighty":-11.721364,"marketCap":735830305},{"date":"2024-06-14","current":-17.322989,"twenty":-16.966549,"median":-15.024031,"eighty":-12.769392,"marketCap":888807905},{"date":"2024-06-21","current":-15.733266,"twenty":-17.881887,"median":-15.772475,"eighty":-14.348329,"marketCap":807242405},{"date":"2024-06-28","current":-16.581593,"twenty":-17.17471,"median":-16.18238,"eighty":-14.635158,"marketCap":850768389},{"date":"2024-07-05","current":-17.059223,"twenty":-17.829134,"median":-16.431888,"eighty":-15.672154,"marketCap":875274616},{"date":"2024-07-12","current":-18.299635,"twenty":-18.057796,"median":-16.595851,"eighty":-15.733266,"marketCap":938917651},{"date":"2024-07-19","current":-14.343149,"twenty":-18.092899,"median":-16.610109,"eighty":-15.733266,"marketCap":735918314},{"date":"2024-07-26","current":-16.431888,"twenty":-18.057796,"median":-16.50674,"eighty":-14.592658,"marketCap":843087333},{"date":"2024-08-02","current":-15.740395,"twenty":-18.021611,"median":-16.417631,"eighty":-14.614044,"marketCap":807608170},{"date":"2024-08-09","current":-11.062669,"twenty":-17.829134,"median":-16.189509,"eighty":-14.507112,"marketCap":697147270},{"date":"2024-08-16","current":-12.078391,"twenty":-17.822005,"median":-15.897228,"eighty":-14.341434,"marketCap":761156070},{"date":"2024-08-23","current":-12.943207,"twenty":-17.322989,"median":-15.776039,"eighty":-12.769083,"marketCap":815654991},{"date":"2024-08-30","current":-12.623979,"twenty":-17.301602,"median":-15.672154,"eighty":-12.252515,"marketCap":795537939},{"date":"2024-09-06","current":-11.799793,"twenty":-17.107699,"median":-14.956226,"eighty":-12.030797,"marketCap":743599370},{"date":"2024-09-13","current":-11.027844,"twenty":-17.007896,"median":-14.603351,"eighty":-11.813723,"marketCap":694952683},{"date":"2024-09-20","current":-12.322165,"twenty":-16.6871,"median":-14.421566,"eighty":-11.752199,"marketCap":776518182},{"date":"2024-09-27","current":-12.380206,"twenty":-16.587296,"median":-14.342291,"eighty":-11.752199,"marketCap":780175827},{"date":"2024-10-04","current":-12.072587,"twenty":-16.581593,"median":-13.041877,"eighty":-11.742318,"marketCap":760790305},{"date":"2024-10-11","current":-12.798103,"twenty":-16.461829,"median":-12.783593,"eighty":-11.721364,"marketCap":806510876},{"date":"2024-10-18","current":-15.061713,"twenty":-16.461829,"median":-13.041877,"eighty":-11.742318,"marketCap":949159059},{"date":"2024-10-25","current":-14.057599,"twenty":-16.431888,"median":-14.106934,"eighty":-11.752199,"marketCap":885881788},{"date":"2024-11-01","current":-14.289764,"twenty":-16.420482,"median":-14.289764,"eighty":-11.78122,"marketCap":900512371},{"date":"2024-11-08","current":-13.587752,"twenty":-16.360601,"median":-14.196898,"eighty":-11.792828,"marketCap":976225637},{"date":"2024-11-15","current":-10.665545,"twenty":-16.293733,"median":-13.709352,"eighty":-11.752199,"marketCap":766276774},{"date":"2024-11-22","current":-11.755009,"twenty":-16.213426,"median":-13.641207,"eighty":-11.719637,"marketCap":844550392},{"date":"2024-11-29","current":-11.627735,"twenty":-16.188083,"median":-13.405914,"eighty":-11.573511,"marketCap":835406277},{"date":"2024-12-06","current":-10.416089,"twenty":-16.139607,"median":-12.943207,"eighty":-11.450385,"marketCap":748354310},{"date":"2024-12-13","current":-9.555718,"twenty":-15.982774,"median":-12.73716,"eighty":-11.371152,"marketCap":686540097},{"date":"2024-12-20","current":-9.199351,"twenty":-15.858733,"median":-12.415031,"eighty":-11.254059,"marketCap":660936577},{"date":"2024-12-27","current":-9.688083,"twenty":-15.824515,"median":-12.350651,"eighty":-11.045256,"marketCap":696049976},{"date":"2025-01-03","current":-9.917175,"twenty":-15.797425,"median":-12.316361,"eighty":-10.975704,"marketCap":712509382},{"date":"2025-01-10","current":-7.539701,"twenty":-15.740395,"median":-12.304752,"eighty":-10.859002,"marketCap":541697328},{"date":"2025-01-17","current":-6.460419,"twenty":-15.733266,"median":-12.215086,"eighty":-10.644772,"marketCap":464155239},{"date":"2025-01-24","current":-7.076424,"twenty":-15.684376,"median":-12.087097,"eighty":-10.43238,"marketCap":508412752},{"date":"2025-01-31","current":-8.354253,"twenty":-15.597056,"median":-11.915876,"eighty":-10.137105,"marketCap":600219659},{"date":"2025-02-07","current":-8.211706,"twenty":-15.257893,"median":-11.843324,"eighty":-9.686047,"marketCap":589978251},{"date":"2025-02-14","current":-8.094614,"twenty":-15.103195,"median":-11.828814,"eighty":-9.441681,"marketCap":581565666},{"date":"2025-02-21","current":-6.455328,"twenty":-15.070846,"median":-11.799793,"eighty":-9.297098,"marketCap":463789474},{"date":"2025-02-28","current":-5.106225,"twenty":-15.037336,"median":-11.771597,"eighty":-9.077168,"marketCap":366861863},{"date":"2025-03-07","current":-4.373128,"twenty":-15.01412,"median":-11.747556,"eighty":-8.771711,"marketCap":314191765},{"date":"2025-03-14","current":-4.898381,"twenty":-14.977526,"median":-11.717047,"eighty":-8.416363,"marketCap":383577552},{"date":"2025-03-21","current":-4.530187,"twenty":-14.817535,"median":-11.627735,"eighty":-8.164869,"marketCap":354745367},{"date":"2025-03-28","current":-4.68399,"twenty":-14.676319,"median":-11.461087,"eighty":-7.790176,"marketCap":366789191},{"date":"2025-04-04","current":-4.189957,"twenty":-14.640334,"median":-11.410917,"eighty":-7.133443,"marketCap":328102968},{"date":"2025-04-11","current":-4.315796,"twenty":-14.632186,"median":-11.370643,"eighty":-6.989878,"marketCap":337957006},{"date":"2025-04-17","current":-4.730597,"twenty":-14.622599,"median":-11.327444,"eighty":-6.74653,"marketCap":370438835},{"date":"2025-04-25","current":-4.949801,"twenty":-14.60549,"median":-11.189913,"eighty":-6.457364,"marketCap":387604034},{"date":"2025-05-02","current":-5.280719,"twenty":-14.55844,"median":-11.048158,"eighty":-5.528775,"marketCap":413517298},{"date":"2025-05-09","current":-4.693792,"twenty":-14.472894,"median":-10.976093,"eighty":-5.332796,"marketCap":374099938},{"date":"2025-05-16","current":-4.560992,"twenty":-14.4176,"median":-10.940782,"eighty":-5.2164,"marketCap":363515647},{"date":"2025-05-23","current":-5.092192,"twenty":-14.397354,"median":-10.8247,"eighty":-5.097805,"marketCap":405852811},{"date":"2025-05-30","current":-3.896992,"twenty":-14.370288,"median":-10.665545,"eighty":-4.981023,"marketCap":310594193},{"date":"2025-06-06","current":-5.646289,"twenty":-14.346875,"median":-10.527934,"eighty":-4.950803,"marketCap":450014853},{"date":"2025-06-13","current":-5.101351,"twenty":-14.342806,"median":-10.416089,"eighty":-4.981023,"marketCap":406582762},{"date":"2025-06-20","current":-5.050978,"twenty":-14.341434,"median":-10.309179,"eighty":-5.014344,"marketCap":402568031},{"date":"2025-06-27","current":-5.408165,"twenty":-14.289764,"median":-9.866266,"eighty":-5.000606,"marketCap":431036124},{"date":"2025-07-03","current":-5.513507,"twenty":-14.247974,"median":-9.698265,"eighty":-5.011596,"marketCap":439432031},{"date":"2025-07-11","current":-7.043002,"twenty":-14.172521,"median":-9.586263,"eighty":-5.043651,"marketCap":561334272},{"date":"2025-07-18","current":-6.795718,"twenty":-14.077333,"median":-9.430989,"eighty":-5.078884,"marketCap":541625526},{"date":"2025-07-25","current":-7.610838,"twenty":-13.779001,"median":-9.362262,"eighty":-5.090926,"marketCap":606591391},{"date":"2025-08-01","current":-6.57591,"twenty":-13.6976,"median":-9.168805,"eighty":-5.092192,"marketCap":524106641},{"date":"2025-08-08","current":-6.368661,"twenty":-13.694662,"median":-9.054259,"eighty":-5.099519,"marketCap":562429202},{"date":"2025-08-15","current":-6.17446,"twenty":-13.609134,"median":-8.982986,"eighty":-5.10525,"marketCap":545278924},{"date":"2025-08-22","current":-6.170327,"twenty":-13.473486,"median":-8.4968,"eighty":-5.115317,"marketCap":544913945},{"date":"2025-08-29","current":-6.943168,"twenty":-13.38251,"median":-8.407708,"eighty":-5.122916,"marketCap":613165056},{"date":"2025-09-05","current":-6.343907,"twenty":-13.171889,"median":-8.282979,"eighty":-5.126995,"marketCap":560243072},{"date":"2025-09-12","current":-9.588184,"twenty":-13.020376,"median":-8.364435,"eighty":-5.143059,"marketCap":846751744},{"date":"2025-09-19","current":-14.281097,"twenty":-13.398113,"median":-8.486618,"eighty":-5.165131,"marketCap":1261192245},{"date":"2025-09-26","current":-13.038354,"twenty":-13.650327,"median":-8.934622,"eighty":-5.176938,"marketCap":1151443158},{"date":"2025-10-03","current":-14.902468,"twenty":-13.718742,"median":-9.051713,"eighty":-5.195691,"marketCap":1316066789},{"date":"2025-10-10","current":-13.962579,"twenty":-13.896787,"median":-9.158623,"eighty":-5.223161,"marketCap":1233063277},{"date":"2025-10-16","current":-13.461305,"twenty":-13.865457,"median":-9.199351,"eighty":-5.252778,"marketCap":1188794738}],"updateTime":1760739427101},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAPP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2566952752","title":"美國研究綜述-Chewy、Phillips 66、Vimeo","url":"https://stock-news.laohu8.com/highlight/detail?id=2566952752","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566952752?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 15:57","pubTimestamp":1757577462,"startTime":"0","endTime":"0","summary":"美国研究综述-Chewy、Phillips 66、Vimeo路透社9月11日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价，其中包括 Chewy、Phillips 66 和 Vimeo。要闻* Chewy公司CHWY.N：摩根大通将目标价从47美元下调至45美元 * Phillips 66 PSX.N：Piper Sandler将目标价从144美元上调至154美元 * Vimeo Inc VMEO.O：Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nL3T3UY0HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CASY","CAMP","LU0130102774.USD","LU0980610538.SGD","DINO","FROG","BK4200","PARR","PSX","LU1267930227.SGD","BK4138","BK4084","IE00B3CCJ963.GBP","LU0266512127.USD","NEUP","IE0009354923.USD","LU0208291251.USD","LU0130517989.USD","IE00BGHQF524.EUR","IE00B3T34201.USD","WK","MNSH","BK4202","LU1169589451.USD","LU1169590202.USD","LU0345780950.USD","LU1941712264.USD","BK4585","LU1559883803.SGD","BK4113","LU0566484027.USD","BK4139","VLO","LU0310800965.SGD","BK4023","PBF","DK","RBRK","VMEO","MPC","TPR","LU0368265418.SGD","IE00B2Q91V27.USD","LU1941712348.USD","WY","LU0757428866.USD","BK4221","CHWY","RAPP"],"gpt_icon":0},{"id":"2566757952","title":"美國研究綜述-Chewy、Phillips 66、Vimeo","url":"https://stock-news.laohu8.com/highlight/detail?id=2566757952","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566757952?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 15:57","pubTimestamp":1757577462,"startTime":"0","endTime":"0","summary":"美国研究综述-Chewy、Phillips 66、Vimeo路透社9月11日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价，其中包括 Chewy、Phillips 66 和 Vimeo。要闻* Chewy公司CHWY.N：摩根大通将目标价从47美元下调至45美元 * Phillips 66 PSX.N：Piper Sandler将目标价从144美元上调至154美元 * Vimeo Inc VMEO.O：Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nL3S3UY0HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4221","IE00B3T34201.USD","TPR","CHWY","NEUP","DK","RBRK","LU0266512127.USD","PSX","LU1169590202.USD","BK4202","BK4200","MPC","RAPP","LU0345780950.USD","LU1267930227.SGD","LU0757428866.USD","MNSH","LU0310800965.SGD","FROG","BK4139","CASY","IE0009354923.USD","DINO","IE00B3CCJ963.GBP","LU0208291251.USD","LU1559883803.SGD","BK4113","BK4084","PARR","LU0130517989.USD","LU0130102774.USD","WY","LU1941712348.USD","LU1941712264.USD","LU0980610538.SGD","VLO","IE00BGHQF524.EUR","LU1169589451.USD","CAMP","LU0566484027.USD","PBF","IE00B2Q91V27.USD","BK4138","LU0368265418.SGD","BK4023","WK","VMEO"],"gpt_icon":0},{"id":"2566988061","title":"美股週三早盤專注於中樞神經系統（CNS）疾病創新療法研發的生物製藥公司Rapport Therapeutics股價重挫此","url":"https://stock-news.laohu8.com/highlight/detail?id=2566988061","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566988061?lang=zh_tw&edition=fundamental","pubTime":"2025-09-10 23:46","pubTimestamp":1757519183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","LENZ","RAPP","BK4135","BK4007","BK4539","CNS"],"gpt_icon":0},{"id":"2566600190","title":"生物製藥公司Rapport重挫18.8%，此前完成2.5億美元的公開發行","url":"https://stock-news.laohu8.com/highlight/detail?id=2566600190","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566600190?lang=zh_tw&edition=fundamental","pubTime":"2025-09-10 22:54","pubTimestamp":1757516040,"startTime":"0","endTime":"0","summary":"美股周三早盘，专注于中枢神经系统（CNS）疾病创新疗法研发的生物制药公司Rapport Therapeutics（RAPP）股价重挫18.8%，此前该公司以每股26美元的价格完成2.5亿美元的公开发行。\n　　此次发行预计将于2025年9月11日完成，所筹资金将用于支持公司的增长计划。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-09-10/doc-infpzray3944272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["RAPP","BK4135","BK4007","CNS"],"gpt_icon":0},{"id":"2566677768","title":"BUZZ-Rapport Therapeutics 募資 2.5 億美元后業績下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2566677768","media":"路透中文","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566677768?lang=zh_tw&edition=fundamental","pubTime":"2025-09-10 18:29","pubTimestamp":1757500140,"startTime":"0","endTime":"0","summary":"** Rapport TherapeuticsRAPP.O在后续发行定价后，股价在收盘前下跌 2.5%，至 27.34 美元。** 该公司在周二晚些时候宣布，  ~960万股，发行价为26美元，募集资金总额为2.5亿美元。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nL3T3UX0QH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345769631.USD","LU1162221912.USD","LU0098860793.USD","LU1732799900.SGD","LU1032466523.USD","LU2471134523.USD","JNJ","LU2471134952.CNY","RAPP","LU0114720955.EUR","BK4592","BK4532","IE00B19Z3581.USD","LU0070217475.USD","LU1868836591.USD","IE0004086264.USD","LU1778281490.HKD","IE00B4R5TH58.HKD","LU1066051225.USD","LU1057294990.SGD","LU2430703095.HKD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU1868836757.USD","LU1894683348.USD","LU0795875086.SGD","LU2237443549.SGD","LU1221951046.USD","IE00B42XCP33.USD","LU0234570918.USD","LU1894683264.USD","BK4581","IE000M9KFDE8.USD","IE00B1BXHZ80.USD","LU1791807156.HKD","IE00BBT3K403.USD","LU1430594728.SGD","BK4007","SF","LU1267930813.SGD","LU2089984988.USD","BK4534","IE00BGHQF631.EUR","LU0058720904.USD","LU0640476718.USD","LU0061475181.USD","LU0234572021.USD","IE00BJT1NW94.SGD","LU0432979614.USD","LU2237438978.USD"],"gpt_icon":0},{"id":"1160286321","title":"Rapport Therapeutics Inc.按每股26.00美元價格公開發行960萬股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1160286321","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160286321?lang=zh_tw&edition=fundamental","pubTime":"2025-09-10 09:19","pubTimestamp":1757467151,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc.宣布以每股26.00美元的价格公开发行960万股普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2566866487","title":"美國研究綜述-IQVIA Holdings、Reliance、United Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2566866487","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566866487?lang=zh_tw&edition=fundamental","pubTime":"2025-09-09 15:29","pubTimestamp":1757402943,"startTime":"0","endTime":"0","summary":"美国研究综述-IQVIA Holdings、Reliance、United Therapeutics路透社9月9日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 IQVIA Holdings、Reliance 和 United Therapeutics。要点 * IQVIA Holdings Inc IQV.N：杰富瑞将其评级从 \"持有 \"上调至 \"买入 * 信实公司RS.N：摩根大通给予增持评级 * United Therapeutics Corp UTHR.O：摩根大通将目标价从345美元上调至450美元以下是路透社周二报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nL3S3UW0GD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130102774.USD","LU1064131342.USD","CRL","LU2098885051.SGD","SEE","SATS","HSY","INSM","UTHR","BAC","MEDP","CMG","ELF","IE00B19Z3581.USD","TASK","EPAM","EMN","LU0882574055.USD","BK4100","LU1988902786.USD","SRPT","RAPP","CEG","APEI","FDS","IE00BLSP4239.USD","IE0004445239.USD","LU0047713382.USD","RS","BK4212","LU1861217088.USD","FTRE","BK4089","BMI","LU2089283258.USD","WING","BK4007","NGS","TKO","IQV","LU1951198990.SGD","LU2065731478.USD","LU1894683348.USD","PIPR","LU2095319765.USD","LU0158827948.USD","SGXZ81514606.USD","LU0528227936.USD"],"gpt_icon":1},{"id":"2566637280","title":"Pmv Pharmaceuticals, Inc.盤中異動 股價大跌5.14%報1.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566637280","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566637280?lang=zh_tw&edition=fundamental","pubTime":"2025-09-08 23:46","pubTimestamp":1757346380,"startTime":"0","endTime":"0","summary":"北京时间2025年09月08日23时46分，Pmv Pharmaceuticals, Inc.股票出现波动，股价大幅下跌5.14%。截至发稿，该股报1.39美元/股，成交量37.4323万股，换手率0.71%，振幅4.45%。Pmv Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.19%。其相关个股中，Rapport Therapeutics, Inc.、Yd Bio Ltd C/Wts 28/08/2030、Acrivon Therapeutics, Inc.涨幅较大，Cdt Equity Inc.、Genprex, Inc.、Indaptus Therapeutics, Inc.较为活跃，换手率分别为849.92%、458.29%、74.80%，振幅较大的相关个股有Rapport Therapeutics, Inc.、Genprex, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026，振幅分别为105.96%、73.86%、47.89%。Pmv Pharmaceuticals, Inc.公司简介：PMV Pharmaceuticals Inc是一家精密肿瘤学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908234621a4bbb4d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908234621a4bbb4d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"1127369274","title":"異動解讀 | 癲癇藥物臨牀試驗成功，Rapport Therapeutics盤前大漲171.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127369274","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127369274?lang=zh_tw&edition=fundamental","pubTime":"2025-09-08 18:46","pubTimestamp":1757328398,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc.今日盘前股价大涨171.59%，引发市场广泛关注。这一显著涨幅主要源于该公司宣布其实验性癫痫药物RAP-219在中期临床试验中取得积极结果。根据公司公布的数据，RAP-219在针对难以治疗的局灶性癫痫发作成人患者的2a期临床试验中表现出色。Rapport Therapeutics表示，计划在2025年第四季度与美国食品药品监督管理局举行2期试验结束会议，并有意在2026年第三季度启动两项后期研究。考虑到该公司此前年内股价累计下跌19.5%，这次利好消息无疑为投资者注入了新的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RAPP"],"gpt_icon":1},{"id":"1191517947","title":"Rapport Therapeutics公佈局灶性癲癇發作試驗積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1191517947","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191517947?lang=zh_tw&edition=fundamental","pubTime":"2025-09-08 18:42","pubTimestamp":1757328127,"startTime":"0","endTime":"0","summary":"9月8日 - Rapport Therapeutics Inc.宣布其RAP-219药物在局灶性癫痫发作患者中的2A期临床试验取得积极的顶线结果。\n试验达到主要终点，RAP-219耐受性良好。\n患者癫痫发作减少77.8%，24%的患者实现无癫痫发作状态。\nRAP-219耐受性良好，不良事件轻微。\n公司计划在2025年第四季度与美国食品药品监督管理局(FDA)举行2期试验结束会议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2565668887","title":"BUZZ-癲癇藥物在中期試驗中達到主要目標，Rapport Therapeutics 公司業績大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2565668887","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565668887?lang=zh_tw&edition=fundamental","pubTime":"2025-09-08 18:27","pubTimestamp":1757327265,"startTime":"0","endTime":"0","summary":"** Rapport公司表示，计划在今年晚些时候与美国监管机构会面，并在2026年第三季度启动两项后期研究。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nL3T3UV0PH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"1101085848","title":"Rapport Therapeutics股價盤前大漲75.5%，局灶性癲癇發作治療藥物中期試驗數據表現積極","url":"https://stock-news.laohu8.com/highlight/detail?id=1101085848","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101085848?lang=zh_tw&edition=fundamental","pubTime":"2025-09-08 18:10","pubTimestamp":1757326214,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics股价在盘前交易中暴涨75.5%，该公司公布的局灶性癫痫发作治疗药物中期试验数据表现良好，推动股价大幅上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"1173937408","title":"Rapport Therapeutics, Inc.公佈Rap-219治療局灶性癲癇發作患者2a期臨牀試驗積極頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1173937408","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173937408?lang=zh_tw&edition=fundamental","pubTime":"2025-09-08 18:00","pubTimestamp":1757325627,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc.宣布其药物Rap-219在治疗局灶性癫痫发作患者的2a期临床试验中取得积极的顶线结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"1118444204","title":"Rapport Therapeutics將於2025年9月8日週一公佈Rap-219治療局灶性癲癇發作2a期臨牀試驗的初步數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1118444204","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118444204?lang=zh_tw&edition=fundamental","pubTime":"2025-09-06 04:06","pubTimestamp":1757102776,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics将于2025年9月8日周一公布Rap-219治疗局灶性癫痫发作2a期临床试验的初步数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2556828913","title":"預計 Rapport Therapeutics Inc  每股虧損 83 美分 - 財報前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2556828913","media":"路透中文","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556828913?lang=zh_tw&edition=fundamental","pubTime":"2025-08-04 21:21","pubTimestamp":1754313669,"startTime":"0","endTime":"0","summary":"预计 Rapport Therapeutics Inc  每股亏损 83 美分 - 财报前瞻) Rapport Therapeutics Inc RAPP.OQ RAPP.O将于8月6日公布截至2025年6月30日的财报(，预计季度收入不会有变化。LSEG 的分析师平均预计 Rapport Therapeutics Inc 每股亏损 83 美分。华尔街对 Rapport Therapeutics Inc 的 12 个月目标价中位数为 35.00 美元，比上一交易日收盘价 14.15 美元高出约 59.6%。8月4日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。如有任何其他问题或反馈，请联系 RefinitivNewsSupport@thomsonreuters.com。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nL4S3TW138:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"gpt_icon":0},{"id":"2539016296","title":"【納斯達克生物科技指數收漲超2%】 成分股Oric Pharma收漲33.50%，Erasca漲32.73%，Tango Therapeutics漲20.10%表現第三。萊斯康製藥則收跌5.66%跌幅第三大，Rapport Therapeutics跌10.46%，Intellia Therapeutics也跌22.88%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2539016296","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539016296?lang=zh_tw&edition=fundamental","pubTime":"2025-05-30 04:53","pubTimestamp":1748551986,"startTime":"0","endTime":"0","summary":"成分股Oric Pharma收涨33.50%，Erasca涨32.73%，Tango Therapeutics涨20.10%表现第三。莱斯康制药则收跌5.66%跌幅第三大，Rapport Therapeutics跌10.46%，Intellia Therapeutics也跌22.88%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/30045350753450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["MNQmain","BK4539","LENZ","USAW.SI","BK4139","TQQQ","PSQ","ERAS","RAPP",".IXIC","QID","BK4007","ARTL","LXRX","NQmain","SQQQ","159632","TSYW.SI","USJW.SI","159837","NVIW.SI","QLD","BK1147","03086"],"gpt_icon":0},{"id":"2537942719","title":"Rapport Therapeutics, Inc.盤中異動 早盤股價大漲5.18%報10.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537942719","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537942719?lang=zh_tw&edition=fundamental","pubTime":"2025-05-22 21:57","pubTimestamp":1747922267,"startTime":"0","endTime":"0","summary":"北京时间2025年05月22日21时57分，Rapport Therapeutics, Inc.股票出现波动，股价大幅上涨5.18%。截至发稿，该股报10.56美元/股，成交量1.7325万股，换手率0.05%，振幅12.55%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.27%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052221574894ff44fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052221574894ff44fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4007","LENZ","BK4139","RAPP"],"gpt_icon":0},{"id":"2537936723","title":"Rapport Therapeutics, Inc.盤中異動 快速拉昇9.59%報11.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537936723","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537936723?lang=zh_tw&edition=fundamental","pubTime":"2025-05-21 21:39","pubTimestamp":1747834789,"startTime":"0","endTime":"0","summary":"北京时间2025年05月21日21时39分，Rapport Therapeutics, Inc.股票出现异动，股价急速拉升9.59%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521213949a6e78623&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521213949a6e78623&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RAPP","BK4539","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2536758475","title":"Rapport Therapeutics, Inc.2025財年第一財季實現淨利潤-24.06百萬美元，同比減少6.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536758475","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536758475?lang=zh_tw&edition=fundamental","pubTime":"2025-05-18 00:00","pubTimestamp":1747497627,"startTime":"0","endTime":"0","summary":"5月18日，Rapport Therapeutics, Inc.公布财报，公告显示公司2025财年第一财季净利润为-24.06百万美元，同比减少6.13%；其中营业收入为0.00美元，每股基本收益为-0.68美元。从资产负债表来看，Rapport Therapeutics, Inc.总负债16.22百万美元，其中短期债务1.01百万美元，资产负债比为0.19，流动比率为0.32。机构评级：截至2025年5月18日，当前有4家机构对Rapport Therapeutics, Inc.目标价做出预测，其中目标均价为35.00美元，其中最低目标价为28.00美元，最高目标价为42.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000148a6e2d816&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000148a6e2d816&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","RAPP"],"gpt_icon":0},{"id":"2536341025","title":"Rapport Therapeutics, Inc.盤中異動 下午盤急速拉昇5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536341025","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536341025?lang=zh_tw&edition=fundamental","pubTime":"2025-05-17 02:30","pubTimestamp":1747420243,"startTime":"0","endTime":"0","summary":"北京时间2025年05月17日02时30分，Rapport Therapeutics, Inc.股票出现波动，股价大幅上涨5.48%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.53%。其相关个股中，Affimed N.V.、Inozyme Pharma, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026涨幅较大，Affimed N.V.、Polyrizon Ltd.、Nucana Plc较为活跃，换手率分别为5229.16%、3626.10%、1686.07%，振幅较大的相关个股有Affimed N.V.、Onconetix, Inc.、Vor Biopharma Inc.，振幅分别为466.98%、66.89%、66.82%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517023043a48136da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517023043a48136da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","RAPP","BK4539","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}